FIRST-QUARTER EARNINGS PREVIEW: Amgen, Biogen, Celgene
This article was originally published in Scrip
Amgen’s shares have been on a tear, rising more than a third in the past three months. Bad news for a competitor in the dialysis market and a surprise upside for an experimental melanoma drug helped lift the stock. (scripintelligence.com March 20)
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.